BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29297493)

  • 21. Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG.
    Wasmuth EV; Hoover EA; Antar A; Klinge S; Chen Y; Sawyers CL
    Proc Natl Acad Sci U S A; 2020 Apr; 117(15):8584-8592. PubMed ID: 32220959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing.
    Pflueger D; Terry S; Sboner A; Habegger L; Esgueva R; Lin PC; Svensson MA; Kitabayashi N; Moss BJ; MacDonald TY; Cao X; Barrette T; Tewari AK; Chee MS; Chinnaiyan AM; Rickman DS; Demichelis F; Gerstein MB; Rubin MA
    Genome Res; 2011 Jan; 21(1):56-67. PubMed ID: 21036922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
    Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
    Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular alterations in prostate cancer and association with MRI features.
    Lee D; Fontugne J; Gumpeni N; Park K; MacDonald TY; Robinson BD; Sboner A; Rubin MA; Mosquera JM; Barbieri CE
    Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):430-435. PubMed ID: 28762374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Expression of Proto-Oncogene
    Khosh Kish E; Choudhry M; Gamallat Y; Buharideen SM; D D; Bismar TA
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
    Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N
    Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Squamous Transformation of Prostate Adenocarcinoma: A Report of Two Cases With Genomic Profiling.
    Dizman N; Salgia M; Ali SM; Wu H; Arvanitis L; Chung JH; Pal SK
    Clin Genitourin Cancer; 2020 Jun; 18(3):e289-e292. PubMed ID: 31882336
    [No Abstract]   [Full Text] [Related]  

  • 28. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
    Tsourlakis MC; Eleftheriadou A; Stender A; Weigand P; Grupp K; Hube-Magg C; Kluth M; Schroeder C; Steurer S; Hinsch A; Luebke A; Angerer A; Wittmer C; Friedrich E; Göbel C; Büscheck F; Heinzer H; Graefen M; Simon R; Sauter G; Wilczak W; Minner S; Schlomm T; Jacobsen F
    Carcinogenesis; 2017 Dec; 38(12):1180-1187. PubMed ID: 29029032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TP53, SPOP and PIK3CA Genes Status in Prostate Cancer.
    Al Zoubi MS; Otoum R; Alorjani MS; Al Bashir S; Al Trad B; Abualrja MI; Al-Khatib SM; Al-Batayneh K
    Asian Pac J Cancer Prev; 2020 Nov; 21(11):3365-3371. PubMed ID: 33247697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
    Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C
    PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alzheimer Gene BIN1 may Simultaneously Influence Dementia Risk and Androgen Deprivation Therapy Dosage in Prostate Cancer.
    Lehrer S; Rheinstein PH
    Am J Clin Oncol; 2020 Oct; 43(10):685-689. PubMed ID: 32568785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer.
    Kluth M; Galal R; Krohn A; Weischenfeldt J; Tsourlakis C; Paustian L; Ahrary R; Ahmed M; Scherzai S; Meyer A; Sirma H; Korbel J; Sauter G; Schlomm T; Simon R; Minner S
    Int J Oncol; 2015 Apr; 46(4):1637-42. PubMed ID: 25625310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Dangerous liaisons in prostate cancer. Clinical and biological implications of recurrent gene fusions].
    Perner S
    Pathologe; 2010 Oct; 31 Suppl 2():121-5. PubMed ID: 20798944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct Genomic Alterations in Prostate Tumors Derived from African American Men.
    Liu W; Zheng SL; Na R; Wei L; Sun J; Gallagher J; Wei J; Resurreccion WK; Ernst S; Sfanos KS; Isaacs WB; Xu J
    Mol Cancer Res; 2020 Dec; 18(12):1815-1824. PubMed ID: 33115829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
    Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
    Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.
    Miyagi Y; Sasaki T; Fujinami K; Sano J; Senga Y; Miura T; Kameda Y; Sakuma Y; Nakamura Y; Harada M; Tsuchiya E
    Mod Pathol; 2010 Nov; 23(11):1492-8. PubMed ID: 20693979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complex patterns of ETS gene alteration arise during cancer development in the human prostate.
    Clark J; Attard G; Jhavar S; Flohr P; Reid A; De-Bono J; Eeles R; Scardino P; Cuzick J; Fisher G; Parker MD; Foster CS; Berney D; Kovacs G; Cooper CS
    Oncogene; 2008 Mar; 27(14):1993-2003. PubMed ID: 17922029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
    Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
    Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
    Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
    Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deletion of 8p is an independent prognostic parameter in prostate cancer.
    Kluth M; Amschler NN; Galal R; Möller-Koop C; Barrow P; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Steurer S; Krech T; Büscheck F; Clauditz TS; Beyer B; Wilczak W; Graefen M; Huland H; Minner S; Schlomm T; Sauter G; Simon R
    Oncotarget; 2017 Jan; 8(1):379-392. PubMed ID: 27880722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.